Cyamemazine
Star1
Identification
- Generic Name
- Cyamemazine
- DrugBank Accession Number
- DB09000
- Background
Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety. Cyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 323.455
Monoisotopic: 323.145618377 - Chemical Formula
- C19H21N3S
- Synonyms
- Cyamemazine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when Cyamemazine is combined with 1,2-Benzodiazepine. Acebutolol The serum concentration of Acebutolol can be increased when it is combined with Cyamemazine. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Cyamemazine. Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Cyamemazine. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Cyamemazine. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Tercian (Sanofi-Aventis)
Categories
- ATC Codes
- N05AA06 — Cyamemazine
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzothiazines
- Sub Class
- Phenothiazines
- Direct Parent
- Phenothiazines
- Alternative Parents
- Alkyldiarylamines / Diarylthioethers / Benzenoids / 1,4-thiazines / Trialkylamines / Nitriles / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- Alkyldiarylamine / Amine / Aromatic heteropolycyclic compound / Aryl thioether / Azacycle / Benzenoid / Carbonitrile / Diarylthioether / Hydrocarbon derivative / Nitrile
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- A2JGV5CNU4
- CAS number
- 3546-03-0
- InChI Key
- SLFGIOIONGJGRT-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H21N3S/c1-14(12-21(2)3)13-22-16-6-4-5-7-18(16)23-19-9-8-15(11-20)10-17(19)22/h4-10,14H,12-13H2,1-3H3
- IUPAC Name
- 10-[3-(dimethylamino)-2-methylpropyl]-10H-phenothiazine-2-carbonitrile
- SMILES
- CC(CN(C)C)CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C#N
References
- Synthesis Reference
U.S. Patent 2,877,224.
- General References
- Not Available
- External Links
- KEGG Drug
- D07307
- PubChem Compound
- 62865
- PubChem Substance
- 310264961
- ChemSpider
- 56597
- BindingDB
- 86057
- 21877
- ChEBI
- 135379
- ChEMBL
- CHEMBL2104153
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Cyamemazine
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 204-205 U.S. Patent 2,877,224. - Predicted Properties
Property Value Source Water Solubility 0.029 mg/mL ALOGPS logP 4.28 ALOGPS logP 4.27 Chemaxon logS -4 ALOGPS pKa (Strongest Basic) 9.42 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 30.27 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 99.09 m3·mol-1 Chemaxon Polarizability 36.48 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-052r-4091000000-8fd4f49543d5acc4171d Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0fk9-0809000000-e9a47ba9e9b612c317f0 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-00di-0029000000-688c415606fcea11bb52 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-00di-0029000000-bace050610190a6af660 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0q29-9355000000-66285b2e31caa1879c98 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-00dr-0190000000-0d53fef3947fb7c85f1c Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-056r-5290000000-0730f877de6790187b95 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 167.3835 predictedDeepCCS 1.0 (2019) [M+H]+ 169.7415 predictedDeepCCS 1.0 (2019) [M+Na]+ 176.07875 predictedDeepCCS 1.0 (2019)
Drug created at June 17, 2014 16:28 / Updated at February 21, 2021 18:52